ClinicalTrials.gg
RecruitingNCT07217405Updated Apr 24, 2026

Radiotherapy Compared to Corticosteroid Injection for Treatment of Hand Osteoarthritis

A Phase 4 interventional study of Corticosteroid injection (CSI) and Low-dose radiotherapy (LDRT) in Osteoarthritis Hand and Osteoarthritis Wrist, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Osteoarthritis by Mayo Clinic — 2 open to participants now, 4 under way, 1 of them phase 3. Osteoarthritis · Mayo Clinic.

Planned enrollment
4th of 19
165 · median 40
Started
2025
with 1 other
Phase 4
3 of 21
1 open now
Registered
21st of 21
by date

Among the 21 studies in Osteoarthritis by Mayo Clinic, this one is the 4th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 4, and was the 21st registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 21 studies in Osteoarthritis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Osteoarthritis by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to compare low-dose radiotherapy to corticosteroid injection for treatment of hand/wrist osteoarthritis.

03

Conditions studied

  • Osteoarthritis Hand
  • Osteoarthritis Wrist

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient at Mayo Clinic, Rochester, MN
  • Age 50 years or older
  • Mild, moderate, or severe hand OA (Kellgren and Lawrence classification grade 2, 3, or 4) on hand radiographs within the last 24 months
  • Hand OA pain with a minimum VAS score relating to hand pain of ≥40 (on a 100-point scale) when using the affected hand
  • Ability to complete study questionnaires

Exclusion criteria

Exclusion Criteria:

  • History of previous surgery to the affected hand(s)
  • joint disease such as rheumatoid arthritis or psoriatic arthritis
  • Active confounding hand condition such as stenosing tenosynovitis or Dupuytren's contracture
  • Recent injury (within last 1 month) to the affected hand causing current pain
  • History of crystalline arthritis (gout or pseudogout) flare in the affected hand(s)
  • Active use of opioid pain medication(s) or oral within the last 3 months
  • Fibromyalgia or central sensitization syndrome
  • Hand CSI or other hand injection within the past 3 months
  • History of hand LDRT within the past 3 months
  • Poorly controlled diabetes ( > 10%)
  • Active infection
  • Current pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Low-dose radiotherapy (LDRT)

    Subjects will receive a total of six (6) low-dose radiotherapy (LDRT) treatments for hand osteoarthritis.

    Radiation: Low-dose radiotherapy (LDRT)

  • Active comparator
    Corticosteroid injection (CSI)

    Subjects will receive standard of care corticosteroid injection (CSI) therapy for hand osteoarthritis.

    Drug: Corticosteroid injection (CSI)

Interventions

  • DrugCorticosteroid injection (CSI)

    A maximum of 3 joints will be treated with standard a standard combination of methylprednisolone and lidocaine: * 1st Carpometacarpal (CMC) joint - 20 mg methylprednisolone/0.5 mL 1% lidocaine\* * Radiocarpal (RC) joint - 40 mg methylprednisolone/1 mL 1% lidocaine\* * Scaphotrapeziotrapezoidal (STT) joint - 20 mg methylprednisolone/0.5 mL 1% lidocaine\* * Metacarpophalangeal (MCP) joint - 20 mg methylprednisolone/0.5 mL 1% lidocaine * Interphalangeal (IP) joint - 10 mg methylprednisolone/0.25 mL 1% lidocaine

    Also known as: Methylprednisolone, Lidocaine

  • RadiationLow-dose radiotherapy (LDRT)

    Subjects will be treated with low-dose radiotherapy of 300cGy in 6 fractions, 2-3 times per week on non-consecutive days. Non-responders to the initial LDRT treatment will receive a second treatment course of 300cGy in 6 fractions to be given 2-3 times per week on non-consecutive days.

06

What researchers measure

Primary outcomes

  1. Change in Visual Analog Scale (VAS) score

    Pain values reported by participants will be assessed using the 100-mm Visual Analogue Scale (VAS). The VAS line will be 100 mm long with no intermediate delineations. Each end will be marked with "no pain" on the left, and "worst possible pain" on the right. Participants will identify their pain level by indicating a point on the line between each end. That point will be measured from the "No pain" end, and the number of millimeters will be reported as the pain score.

    Time frame: Baseline, monthly for 6 months post-intervention, 9 months post-intervention, 12 months post-intervention

Secondary outcomes

  1. Change in Cochin Hand Function Scale scores

    The Cochin Hand Function Scale (CHFS) uses an 18-item, 5-point Likert scale (0 to 5) for scoring, where higher scores indicate greater difficulty with hand function. Scores range from 0 (no difficulty) to 90 (impossible to complete) by summing the ratings for all 18 items. This scale measures the ability to perform daily activities related to the hand, such as kitchen tasks, dressing, and hygiene.

    Time frame: Baseline, monthly for 6 months post-intervention, 9 months post-intervention, 12 months post-intervention

  2. Change in analgesic medication use

    Change in analgesic medication use will be assessed using the Qualitative Analgesic Questionnaire \[QAC\]. The QAC is a 3 question self-report survey tracking current use of pain medications.

    Time frame: Baseline, monthly for 6 months post-intervention, 9 months post-intervention, 12 months post-intervention

  3. Patient experience, as measured by Was It Worth It questionnaire

    The Was It Worth It questionnaire is a 4-question survey consisting of yes/no questions regarding the treatment experience. The greater number of questions with a 'yes' response indicate a higher level of patient satisfaction.

    Time frame: 6 months and 12 months post-intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for May 2027, 16 months after the start.

Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 16 months is below that.

Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2025
First posted
Oct 16, 2025
StartActual
Dec 19, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07217405
Lead sponsor
Mayo Clinic
Responsible party
Terin T. Sytsma (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Oct 16, 2025
Start date
Dec 19, 2025
Primary completion
May 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Apr 24, 2026

Study contacts

Tochukwu Iyke-Nzeocha
Contact
Iyke-Nzeocha.Tochukwu@mayo.edu
(507) 422-3201
Melissa Wang, M.A., CCRP
Contact
wang.melissa@mayo.edu
(507) 266-6911
Terin Sytsma, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion